{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:21:26Z","timestamp":1792801286362,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hyperammonemic encephalopathy is a rare and serious adverse reaction to valproate. Although there is documentation of this reaction in previous reports, very little is still known about the exact mechanism of action. In addition, there are no established guidelines of the next steps needed when a patient does develop this reaction. Therefore, this case report highlights what is known as well as the areas of research still needed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>Our patient was a 57-year-old Caucasian woman with a medical history of bipolar I disorder, opioid use disorder, benzodiazepine use disorder, and Crohn\u2019s disease who was admitted to our behavioral health unit for suicidal ideation. She had been experiencing multiple panic attacks for 2.5\u2009weeks along with poor sleep, increased energy, excessive spending, and feelings of helplessness. The patient was diagnosed with bipolar I disorder, manic episode without psychotic features, and benzodiazepine use disorder. She was started on valproic acid, citalopram, propranolol, and quetiapine. By day 6 of her hospitalization, the patient had altered mental status, varying levels of consciousness, confusion, and ataxic gait. Her ammonia levels were found to be elevated. All of her medications were discontinued, and lactulose was initiated. She returned to her baseline mentation within 48\u2009hours and was discharged with lithium and quetiapine. The treatment team concluded that this patient had valproate-induced hyperammonemic encephalopathy, a rare but reversible reaction to valproate.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Fortunately, rapid identification of this rare condition led to a favorable outcome in our patient. This case report illustrates the course of treatment in a patient who experienced this reaction and reviews current knowledge as well as areas of needed research in regard to valproate-induced hyperammonemic encephalopathy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-2343-x","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T01:02:22Z","timestamp":1579914142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Valproate-induced hyperammonemic encephalopathy: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Suhal","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrick","family":"Vieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"2343_CR1","first-page":"773","volume-title":"Stahl\u2019s essential psychopharmacology: prescriber\u2019s guide","author":"SM Stahl","year":"2017","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology: prescriber\u2019s guide. 6th ed. Cambridge: Cambridge University Press; 2017. p. 773\u20139.","edition":"6"},{"key":"2343_CR2","doi-asserted-by":"publisher","first-page":"217269","DOI":"10.1155\/2014\/217269","volume":"2014","author":"M V\u00e1zquez","year":"2014","unstructured":"V\u00e1zquez M, Fagiolino P, Maldonado C, et al. Hyperammonemia associated with valproic acid concentrations. Biomed Res Int. 2014;2014:217269.","journal-title":"Biomed Res Int"},{"issue":"1","key":"2343_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","volume":"114","author":"N Segura-Bruna","year":"2006","unstructured":"Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006;114(1):1\u20137.","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"2343_CR4","volume":"9","author":"F Farooq","year":"2017","unstructured":"Farooq F, Din JS, Khan AM, Nagvi S, Shagufta S, Mohit A. Valproate-induced hyperammonemic encephalopathy. Cureus. 2017;9(8):e1593.","journal-title":"Cureus"},{"issue":"4","key":"2343_CR5","first-page":"452","volume":"35","author":"N Rodriques-Silva","year":"2013","unstructured":"Rodriques-Silva N, Ven\u00e2ncio \u00c2, Bou\u00e7a J. Risperidone, a risk factor for valproate-induced encephalopathy? Gen Hosp Psychiatry. 2013;35(4):452. e5\u20136","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"2343_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.psym.2017.02.003","volume":"58","author":"C Lewis","year":"2017","unstructured":"Lewis C, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders. Psychosomatics. 2017;58(4):415\u201320.","journal-title":"Psychosomatics"},{"issue":"1","key":"2343_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/ipj.ipj_37_16","volume":"26","author":"VS Chauhan","year":"2017","unstructured":"Chauhan VS, Dixit S, Goyal S, Azad S. Valproate induced hyperammonemic encephalopathy treated by haemodialysis. Ind Psychiatry J. 2017;26(1):99\u2013102.","journal-title":"Ind Psychiatry J"},{"issue":"3","key":"2343_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000345226","volume":"4","author":"D Bega","year":"2012","unstructured":"Bega D, Vaitkevicuis H, Boland TA, Murray M, Chou SH. Fatal hyperammonemic brain injury from valproic acid exposure. Case Rep Neurol. 2012;4(3):224\u201330.","journal-title":"Case Rep Neurol"},{"issue":"1","key":"2343_CR9","first-page":"40","volume":"47","author":"N Patel","year":"2017","unstructured":"Patel N, Landry KB, Pargason RE, Birur B. Reversible encephalopathy due to valproic acid induced hyperammonemia in a patient with bipolar I disorder: a cautionary report. Psychopharmacol Bull. 2017;47(1):40\u20134.","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"2343_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2193-1801-2-13","volume":"2","author":"C Sousa","year":"2013","unstructured":"Sousa C. Valproic acid-induced hyperammonemic encephalopathy \u2013 a potentially fatal adverse drug reaction. Springerplus. 2013;2(1):13.","journal-title":"Springerplus"},{"issue":"2","key":"2343_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/0019-5545.42400","volume":"50","author":"RJ Pradeep","year":"2008","unstructured":"Pradeep RJ. Valproate monotherapy induced-delirium due to hyperammonemia: a report of three adult case with different types of presentation. Indian J Psychiatry. 2008;50(2):121\u20133.","journal-title":"Indian J Psychiatry"},{"issue":"4","key":"2343_CR12","first-page":"VD01","volume":"9","author":"S Dixit","year":"2015","unstructured":"Dixit S, Namdeo M, Azad S. Valproate induced delirium due to hyperammonemia in a case of acute mania: a diagnostic dilemma. J Clin Diagn Res. 2015;9(4):VD01\u20132.","journal-title":"J Clin Diagn Res"},{"issue":"12","key":"2343_CR13","first-page":"FR01","volume":"9","author":"A Muraleedharan","year":"2015","unstructured":"Muraleedharan A, Palappallil DS, Gangadhar R, Das S. Valproate induced hyperammonemic delirium. J Clin Diagn Res. 2015;9(12):FR01\u20133.","journal-title":"J Clin Diagn Res"},{"key":"2343_CR14","doi-asserted-by":"publisher","first-page":"969505","DOI":"10.1155\/2011\/969505","volume":"2011","author":"S Tarafdar","year":"2011","unstructured":"Tarafdar S, Slee M, Ameer F, Doogue M. A case of valproate induced hyperammonemic encephalopathy. Case Rep Med. 2011;2011:969505.","journal-title":"Case Rep Med"},{"issue":"5","key":"2343_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3122\/jabfm.2007.05.070062","volume":"20","author":"J Wadzinski","year":"2007","unstructured":"Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007;20(5):499\u2013502.","journal-title":"J Am Board Fam Med"},{"issue":"7","key":"2343_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/j.1528-1157.2000.tb00263.x","volume":"41","author":"A Kifune","year":"2000","unstructured":"Kifune A, Kubota F, Shibata N, Akata T, Kikuchi S. Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia. 2000;41(7):909\u201312.","journal-title":"Epilepsia"},{"issue":"1","key":"2343_CR17","first-page":"37","volume":"28","author":"K Thomas","year":"2016","unstructured":"Thomas K, La AQ, Punia S, Doroudgar S, Perry PJ. Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. Ann Clin Psychiatry. 2016;28(1):37\u201342.","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"2343_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2146\/ajhp110049","volume":"69","author":"CM Mock","year":"2012","unstructured":"Mock CM, Schwetschenau KH. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. Am J Health Syst Pharm. 2012;69(1):35\u20139.","journal-title":"Am J Health Syst Pharm"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-2343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-2343-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-2343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:06:18Z","timestamp":1611446778000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-2343-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2343"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-2343-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The need for ethical approval was waived by the local institutional review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}